The new article outlines the general considerations associated with the Q-Submission Program to facilitate the process of obtaining feedback from the authority concerning regulatory submissions.
Table of content
The Food and Drug Administration (FDA or the Agency), the US regulating authority in the sphere of healthcare products, has published a revised draft guidance document dedicated to the Q-Submission program introduced to provide medical device manufacturers and other parties involved with the opportunity to obtain substantive feedback from the authority.
Once finalized, the guidance will provide non-binding recommendations and clarifications to be considered by the relevant stakeholders to ensure compliance with respective regulatory requirements.
At the same time, it is essential to mention that FDA guidance documents are non-binding in their legal nature, nor are they intended to introduce new rules or impose new obligations.
Moreover, the authority explicitly states that an alternative approach could be applied, provided such an approach is in line with the existing legal framework. It has been agreed with the authority in advance.
The Q-Submission (Q-Sub) Program represents an important step towards structured and efficient communication between the FDA and medical device manufacturers.
This program facilitates a range of interactions that fall outside the direct submission of Investigational Device Exemptions (IDEs), Investigational New Drug (IND) applications, marketing submissions, Accessory Classification Requests, or Custom Device Exemptions (CDEs).
By utilizing Q-Subs effectively, stakeholders can navigate the premarket process more efficiently, benefiting from the opportunity to discuss, refine, and receive feedback on their products throughout the development lifecycle.
Strategic Use of Q-Submissions
According to the guidance, Q-Subs are critical tools for engaging with the FDA at various product development stages. They allow submitters to:
- Share information and receive FDA input on non-clinical and clinical testing plans.
- Request Breakthrough Device Designations.
- Engage in Informational Meetings to discuss development progress and strategic approaches.
Such interactions are documented within the Q-Sub program, enhancing transparency and providing a record of the evolving discussion between the FDA and the submitter.
Managing Q-Submissions
As further explained by the authority, the program’s design encourages a thoughtful approach to submitting Q-Subs and their supplements.
Key recommendations include:
- Limiting the Number of Q-Subs: To prevent confusion and inefficiency, submitters should avoid overlapping Q-Subs for the same device. Ideally, only one Q-Sub should be active to focus on the submitter’s current priority.
- Strategic Submission Order: The sequence of Q-Subs can significantly impact the review process. Dependencies may exist, so receiving feedback on one issue is advisable before raising another.
Initial Overview: When planning multiple Q-Subs for a single device, the first submission should outline the expected series of submissions and their general timelines, if known.
Confidentiality and Withdrawal
The scope of the guidance also covers the aspects related to confidentiality and withdrawals, namely:
- Confidentiality: The FDA maintains the secrecy of Q-Subs under the Federal Food, Drug, and Cosmetic Act, its regulations, and the Freedom of Information Act.
- Withdrawal Limitations: It cannot be withdrawn once feedback is provided and the Q-Sub file is closed. However, there is no obligation for a follow-on premarket submission based on a Q-Sub.
Conclusion
The Q-Submission Program offers a structured platform for proactive engagement between the FDA and product developers, playing a critical role in the premarket process. This includes effective planning of submission sequences, understanding the unique requirements for combination products, and ensuring that all interactions are geared towards facilitating product development and regulatory approval.
How Can RegDesk Help?
RegDesk is a holistic Regulatory Information Management System that provides medical device and pharma companies with regulatory intelligence for over 120 markets worldwide. It can help you prepare and publish global applications, manage standards, run change assessments, and obtain real-time alerts on regulatory changes through a centralized platform. Our clients also have access to our network of over 4000 compliance experts worldwide to obtain verification on critical questions. Global expansion has never been this simple.
